To determine if there are any coverage restrictions for Vascepa (icosapent ethyl) under your insurance, you would need to consult your specific insurance plan's formulary or contact your insurance provider directly. However, I can provide some general information about Vascepa's patent status and potential insurance implications based on the available information.

Vascepa, developed by Amarin Corporation, is a prescription medication approved by the FDA for reducing the risk of cardiovascular events in adults with elevated triglyceride levels. The drug's active ingredient, icosapent ethyl, is a highly purified form of eicosapentaenoic acid (EPA), an omega-3 fatty acid.

According to DrugPatentWatch.com [1], Vascepa's key patents expired in December 2020 in the United States. This means that generic versions of the drug could potentially become available, which may impact Vascepa's coverage and cost under insurance plans. However, the specifics of how and when generic icosapent ethyl will be covered by various insurance plans can vary.

To get the most accurate information regarding Vascepa's coverage and any potential restrictions under your insurance, it is recommended that you consult your insurance provider's formulary or contact their customer service department.

Sources:
[1] DrugPatentWatch.com - Vascepa (Icosapent Ethyl) - <https://www.drugpatentwatch.com/drugs/vascepa>